36 related articles for article (PubMed ID: 23025267)
1. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.
Zent CS; Call TG; Bowen DA; Conte MJ; LaPlant BR; Witzig TE; Ansell SM; Weiner GJ
Leuk Lymphoma; 2015; 56(8):2373-8. PubMed ID: 25676035
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Brown JR; Messmer B; Werner L; Davids MS; Mikler E; Supko JG; Fisher DC; LaCasce AS; Armand P; Jacobsen E; Dalton V; Tesar B; Fernandes SM; McDonough S; Ritz J; Rassenti L; Kipps TJ; Neuberg D; Freedman AS
Haematologica; 2013 Jun; 98(6):964-70. PubMed ID: 23645694
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
5. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).
Zent CS; Victoria Wang X; Ketterling RP; Hanson CA; Libby EN; Barrientos JC; Call TG; Chang JE; Liu JJ; Calvo AR; Lazarus HM; Rowe JM; Luger SM; Litzow MR; Tallman MS
Am J Hematol; 2016 Mar; 91(3):308-12. PubMed ID: 26662208
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
Flowers CR; Brown JR; Rosenthal H; Stock W; Katzen HI; Cohen JB; Sinha R; Lakhanpal S; Leis JF; Waller EK; Jaye DL
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):694-8. PubMed ID: 26385641
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
Faderl S; Ferrajoli A; Wierda W; O'Brien S; Lerner S; Keating MJ
Cancer; 2010 May; 116(10):2360-5. PubMed ID: 20225334
[TBL] [Abstract][Full Text] [Related]
8. Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis.
Vojdeman FJ; Jurlander J; van't Veer M; Itälä-Remes M; Kimby E; Tjønnfjord GE; Walewski J; Kozák T; Polliack A; Montagna M; Regazzi M; Kirkby N; van Oers M; Geisler CH
Leuk Lymphoma; 2013 Apr; 54(4):790-3. PubMed ID: 23025267
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab in chronic lymphocytic leukemia.
James DF; Kipps TJ
Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
[TBL] [Abstract][Full Text] [Related]
10. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
12. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
